Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma
NCT ID: NCT00487214
Last Updated: 2011-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
361 participants
OBSERVATIONAL
2002-06-30
2003-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
NCT00347841
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00541242
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
NCT02061683
Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
NCT00300443
Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT01068964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Allergan, Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Affairs
Role: STUDY_DIRECTOR
Allergan
Related Links
Access external resources that provide additional context or updates about the study.
(Link to Clinical Trial Results)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEDNET2001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.